Pharma’s pain from the Inflation Reduction Act will be felt well beyond the first 10 brands facing price cuts
Clarivate
SEPTEMBER 5, 2024
Starting in 2026, the first ten self-administered Part D drugs in the law’s cross hairs will receive price cuts of 38%-79%. With the passage of the Inflation Reduction Act (IRA), the United States government gained the ability to directly negotiate drug prices with manufacturers.
Let's personalize your content